Background The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). Materials and methods We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Results Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. Conclusion Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations / Corianò, M.; Lazzarin, A.; Maffezzoli, M.; Santoni, M.; Mazzaschi, G.; Rodella, S.; Simoni, N.; Lai, E.; Maruzzo, M.; Basso, U.; Bimbatti, D.; Iacovelli, R.; Anghelone, A.; Fiala, O.; Rebuzzi, S. E.; Fornarini, G.; Lolli, C.; Massari, F.; Rosellini, M.; Mollica, V.; Nasso, C.; Acunzo, A.; Silini, E. M.; Quaini, F.; De Filippo, M.; Brunelli, M.; Banna, G. L.; Rescigno, P.; Signori, A.; Buti, S.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2025). [10.1080/1750743X.2025.2452145]

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations

Lazzarin A.;Maffezzoli M.
Formal Analysis
;
Mazzaschi G.
Methodology
;
Simoni N.
Writing – Review & Editing
;
Acunzo A.;Silini E. M.
Investigation
;
Quaini F.
Conceptualization
;
De Filippo M.
Writing – Review & Editing
;
Buti S.
Conceptualization
2025-01-01

Abstract

Background The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). Materials and methods We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Results Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. Conclusion Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.
2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations / Corianò, M.; Lazzarin, A.; Maffezzoli, M.; Santoni, M.; Mazzaschi, G.; Rodella, S.; Simoni, N.; Lai, E.; Maruzzo, M.; Basso, U.; Bimbatti, D.; Iacovelli, R.; Anghelone, A.; Fiala, O.; Rebuzzi, S. E.; Fornarini, G.; Lolli, C.; Massari, F.; Rosellini, M.; Mollica, V.; Nasso, C.; Acunzo, A.; Silini, E. M.; Quaini, F.; De Filippo, M.; Brunelli, M.; Banna, G. L.; Rescigno, P.; Signori, A.; Buti, S.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2025). [10.1080/1750743X.2025.2452145]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/3016973
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact